Search Filters

Search Results

Found 1 results

510(k) Data Aggregation

    K Number
    K121534
    Manufacturer
    Date Cleared
    2012-06-20

    (27 days)

    Product Code
    Regulation Number
    862.1660
    Reference & Predicate Devices
    Why did this record match?
    Device Name :

    CONE-TROL HEMOGLOBIN A1C CONTROL SET

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    CONE-TROL Hemoglobin A1c Control Set is intended for use as quality control material to monitor the performance and precision of Hemoglobin A 1 c determination methods.

    Device Description

    The CONE-TROL Hemoglobin A 1c Control Set is prepared from human blood to which chemicals, preservatives, and stabilizers are added. The control is provided in liquid form for user convenience.

    AI/ML Overview

    The provided documentation describes the acceptance criteria and study for the CONE-TROL Hemoglobin A1c Control Set, a quality control material, primarily focusing on its stability. It is not an AI/ML device, so many of the requested fields (e.g., MRMC studies, human reader improvement, multi-reader consensus) are not applicable.

    Here's the breakdown of the available information:

    1. Table of Acceptance Criteria and Reported Device Performance

    The acceptance criterion for the CONE-TROL Hemoglobin A1c Control Set is that the analyte activity (concentration) must fall within ±10% of the initial value at various storage conditions and time points.

    AnalyteAcceptance Criteria (Concentration Range Accepted by Company)Initial ValueReported Performance (Concentration/Percent Change) at different conditions
    Accelerated Closed Vial Stability (37°C, 30 hours)
    HbA1c-Level 14.2-6.4% (implies ±10% around 5.3%)5.3%5.4% (1.89% change)
    HbA1c-Level 28.6-13.0% (implies ±10% around 10.8%)10.8%10.8% (0% change)
    Real Time Closed Vial Stability (-20°C, 210 days)
    HbA1c-Level 14.2-6.4% (implies ±10% around 5.3%)5.3%5.4% (1.89% change)
    HbA1c-Level 29.5-14.3% (implies ±10% around 11.9%)11.9%12.1% (1.68% change)
    Open Vial Stability (2-8°C, 210 days)
    HbA1c-Level 14.2-6.4% (implies ±10% around 5.3%)5.3%5.0% (5.7% change)
    HbA1c-Level 29.5-14.3% (implies ±10% around 11.9%)11.9%11.5% (3.4% change)

    2. Sample Size Used for the Test Set and Data Provenance

    • Sample Size:
      • For stability studies, the "sample" typically refers to the number of vials or batches tested. The document mentions two vials were assayed in triplicate for value assignment, and data points were collected over several days (minimum 6 data points per level for value assignment). For stability, specific numbers of individual vials tested at each time point are not explicitly stated, but it follows a standard protocol of testing representative aliquots from the prepared control sets.
    • Data Provenance: Not explicitly stated (e.g., country of origin, retrospective/prospective). However, the studies were conducted by the manufacturer, Cone Bioproducts, located in Seguin, TX, USA, for regulatory submission to the FDA. The stability studies are prospective, as they track the product over time.

    3. Number of Experts Used to Establish Ground Truth for the Test Set and Qualifications of those Experts

    Not applicable. This device is a quality control material whose "truth" is its chemical concentration, determined by analytical instrumentation. It does not involve human interpretation or expert opinions to establish ground truth in the way an AI diagnostic device would.

    4. Adjudication Method for the Test Set

    Not applicable. Ground truth for this chemical control is established through objective analytical measurements, not through adjudication of expert opinions.

    5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done, If So, What Was the Effect Size of How Much Human Readers Improve with AI vs. Without AI Assistance

    Not applicable. This is not an AI/ML device.

    6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done

    Yes, in a sense, the performance of the control material is assessed in a "standalone" manner. Its stability and value assignment are determined purely through analytical measurements on laboratory instruments (Tosoh G7 HPLC Analyzer). There is no "human-in-the-loop" component in determining the performance of the control material itself; it's an objective measurement of its chemical properties over time.

    7. The Type of Ground Truth Used

    The ground truth used is the measured concentration of HbA1c in the control material, determined by objective analytical methods using the Tosoh G7 HPLC Analyzer. This is a form of measurement data/analytical truth.

    8. The Sample Size for the Training Set

    Not applicable. This is not an AI/ML device, so there is no "training set."

    9. How the Ground Truth for the Training Set Was Established

    Not applicable. As above, there is no training set for this type of device. The "ground truth" for the control material's initial value (value assignment) is established by assaying Levels 1 and 2 in triplicate on the applicable instrument system, with a minimum of 6 data points for each level. The mean, standard deviation, and coefficient of variance are then determined.

    Ask a Question

    Ask a specific question about this device

    Page 1 of 1